<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="other">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CPJ</journal-id>
<journal-id journal-id-type="hwp">spcpj</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Pediatr (Phila)</journal-id>
<journal-title>Clinical Pediatrics</journal-title>
<issn pub-type="ppub">0009-9228</issn>
<issn pub-type="epub">1938-2707</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0009922811430347</article-id>
<article-id pub-id-type="publisher-id">10.1177_0009922811430347</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Brief Reports</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Blistering Skin Disorders in the Neonate</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Rimoin</surname><given-names>Lauren</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0009922811430347">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Graham</surname><given-names>John M.</given-names><suffix>Jr.</suffix></name>
<degrees>MD, ScD</degrees>
<xref ref-type="aff" rid="aff2-0009922811430347">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-0009922811430347"><label>1</label>David Geffen School of Medicine, University of California, Los Angeles, CA, USA</aff>
<aff id="aff2-0009922811430347"><label>2</label>Cedars-Sinai Medical Center, Los Angeles, CA, USA</aff>
<author-notes>
<corresp id="corresp1-0009922811430347">John M. Graham Jr., Medical Genetics Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, PACT Suite 400, Los Angeles, CA 90048, USA Email: <email>john.graham@cshs.org</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>7</month>
<year>2012</year>
</pub-date>
<volume>51</volume>
<issue>7</issue>
<fpage>685</fpage>
<lpage>688</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<sec id="section1-0009922811430347">
<title>Case Report and Hospital Course</title>
<p>An ex-40-week Caucasian baby boy was born via normal spontaneous vaginal delivery to a 32-year old gravida 0, para 0 mother and her 35-year-old husband. The prenatal period was uneventful, although the mother was β-Streptococcus positive and received intrapartum antibiotics. The patient was vigorous at birth with Apgars of 9 and 10 at 1 and 5 minutes, respectively, and no problems were noted. At 14 hours of life, the patient was noted to have blistering and sloughing of scrotal skin as well as a heart murmur, and he was transferred to the neonatal intensive care unit (NICU) for further monitoring. EKG leads were placed and the tape securing the leads resulted in the development of severe blistering of the patient’s skin on his ears, arms, elbows, hands, chest, scrotum, and feet. During his 1-week stay in the NICU, he was treated with antibiotics and intravenous fluids. An inpatient dermatology consultation made at that time resulted in the diagnosis of possible epidermolysis bullosa (EB).</p>
<p>A 3-generation pedigree was obtained. The patient’s mother reported easy blistering of her feet after only 20 minutes of hiking. There were other family members with this problem. Both maternal and paternal relatives were of Western European/non-Jewish decent with no history of consanguinity.</p>
</sec>
<sec id="section2-0009922811430347">
<title>Final Diagnosis and Follow-up</title>
<p>In the first 2 months of life, the patient developed recurrent bullae without scarring on the palms (<xref ref-type="fig" rid="fig1-0009922811430347">Figure 1</xref>), soles, and diaper area. Bullae formation increased with dampness and friction, and the bullae were neither linear nor grouped. No involvement of the oral mucosa, hair, or nails was noted. By 12 months of age, a thick, yellow crust had developed on the skin of his palms, soles (<xref ref-type="fig" rid="fig2-0009922811430347">Figure 2</xref>), nasolabial folds, axilla, posterior neck (<xref ref-type="fig" rid="fig3-0009922811430347">Figure 3</xref>), inguinal creases, and eyebrows. Despite continued application of moisturizing creams, his palms and soles demonstrated erythema with peeling and flaking (<xref ref-type="fig" rid="fig2-0009922811430347">Figure 2</xref>). An unruptured vesicle was biopsied and histopathological evaluation was consistent with epidermolysis bullosa simplex (EBS), which is the most common form of EB, with immunofluoresence demonstrating absent keratin-14. Given these findings, molecular diagnostic testing was performed for keratin-14 and keratin-5, the 2 most commonly mutated genes in EBS. When these genetic tests came back normal, the diagnosis was reassessed and a new diagnosis of epidermolytic hyperkeratosis (EHK) was made. Further genetic testing showed a heterozygous missense mutation of the <italic>KRT1</italic> gene (I479T), which is a previously reported pathogenic mutation in the keratin-1 gene associated with EHK.</p>
<fig id="fig1-0009922811430347" position="float">
<label>Figure 1.</label>
<caption>
<p>Mild blistering and hyperkeratosis of palm at 1 month of age compared with increasing hyperkeratosis at 12 and 24 months</p>
</caption>
<graphic xlink:href="10.1177_0009922811430347-fig1.tif"/>
</fig>
<fig id="fig2-0009922811430347" position="float">
<label>Figure 2.</label>
<caption>
<p>Changes to soles with extensive hyperkeratosis at 12 and 24 months</p>
</caption>
<graphic xlink:href="10.1177_0009922811430347-fig2.tif"/>
</fig>
<fig id="fig3-0009922811430347" position="float">
<label>Figure 3.</label>
<caption>
<p>Extensive hyperkeratosis of posterior neck at 24 months</p>
</caption>
<graphic xlink:href="10.1177_0009922811430347-fig3.tif"/>
</fig>
</sec>
<sec id="section3-0009922811430347">
<title>Discussion</title>
<p>Epidermolytic hyperkeratosis, otherwise known as epidermolytic ichthyosis or bullous congenital ichthyosiform erythroderma, is a rare congenital ichthyosis characterized by the phenotypic triad of skin redness (erythroderma), widespread thickening of the most superficial layer of skin (hyperkeratosis), and skin erosions and peeling with minor trauma (skin fragility).<sup><xref ref-type="bibr" rid="bibr1-0009922811430347">1</xref></sup> With a prevalence of 1 in 200 000 to 300 000 people, the disorder is caused by mutations in <italic>KRT1</italic> or <italic>KRT10</italic>, the 2 genes that encode epidermal suprabasal keratins.<sup><xref ref-type="bibr" rid="bibr1-0009922811430347">1</xref><xref ref-type="bibr" rid="bibr2-0009922811430347"/>-<xref ref-type="bibr" rid="bibr3-0009922811430347">3</xref></sup></p>
<p>At birth, EHK presents with erythroderma accompanied by severe blistering, which are traits that are also seen in subtypes of EB, a distinct mechanobullous genetic disorder.<sup><xref ref-type="bibr" rid="bibr1-0009922811430347">1</xref></sup> These EHK and EB phenotypes diverge with time: The bullous formation in EHK improves with age, and the hyperkeratosis (skin thickening and scaling) appears at 3 to 4 months and persists into adulthood in a palmoplantar distribution.<sup><xref ref-type="bibr" rid="bibr2-0009922811430347">2</xref></sup> In the older patient, it is also common to find hyperkeratosis in the flexural and intertriginous areas, and superinfection of the hyperkeratotic plaques and scales often causes a distinct unpleasant odor.<sup><xref ref-type="bibr" rid="bibr1-0009922811430347">1</xref></sup> Extensive disease can cause loss of distal finger and toe fat pads, leading to decreased hand and foot range of motion and resultant gait abnormalities.<sup><xref ref-type="bibr" rid="bibr4-0009922811430347">4</xref></sup></p>
<p>EHK can be classified into 6 clinical subtypes based on the involvement of palm and sole hyperkeratosis. The NPS (no palm/sole) hyperkeratosis category describes patients without severe palmoplantar lesions and can be broken into 3 types based on other dermatologic findings and gait competency.<sup><xref ref-type="bibr" rid="bibr4-0009922811430347">4</xref></sup> The PS subtype (with palm/sole hyperkeratosis) can similarly be divided into 3 types. A final type of EHK called ichthyosis bullosa of Siemens is characterized by a less severe presentation without palmoplantar lesions.<sup><xref ref-type="bibr" rid="bibr1-0009922811430347">1</xref></sup></p>
<p>The <italic>KRT1</italic> and <italic>KRT10</italic> mutations responsible for EHK are primarily missense mutations passed down in an autosomal dominant fashion, although several recent reports have suggested recessive inheritance of a nonsense <italic>KRT10</italic> mutation.<sup><xref ref-type="bibr" rid="bibr5-0009922811430347">5</xref></sup> Half of all reported cases are due to spontaneous de novo point, deletion, and splice site mutations, so a family history is often not reported.<sup><xref ref-type="bibr" rid="bibr5-0009922811430347">5</xref></sup> There is a clearly established genotype–phenotype correlation in EHK. <italic>KRT1</italic> alterations are associated with hyperkeratosis of the palms and soles, whereas changes in <italic>KRT10</italic> usually result in phenotypes that lack palmoplantar keratoderma.<sup><xref ref-type="bibr" rid="bibr4-0009922811430347">4</xref></sup></p>
<p>Diagnosis is made by skin biopsy and confirmed by genetic testing. Prenatal diagnosis is possible with chorionic vili sampling or amniocentesis with DNA analysis of <italic>KRT1</italic> and <italic>KRT10</italic> mutations.<sup><xref ref-type="bibr" rid="bibr6-0009922811430347">6</xref></sup> Before direct gene sequencing, fetal skin biopsy at 20 to 22 weeks was used to show clumped keratin filaments on electron microscopy.<sup><xref ref-type="bibr" rid="bibr2-0009922811430347">2</xref></sup> It is important to examine parents for epidermal nevi; the presence of linear epidermal nevi along the lines of Blaschko with EHK pathology suggests parents may be gonadal or somatic mosaics and thereby have an increased risk for another affected child.<sup><xref ref-type="bibr" rid="bibr7-0009922811430347">7</xref></sup></p>
<p>Management of EHK centers around hydration, infection control, and oral retinoids for flares in adulthood.<sup><xref ref-type="bibr" rid="bibr2-0009922811430347">2</xref></sup> Neonates should be transferred to the NICU for a sepsis workup and monitoring of fluids and electrolytes.<sup><xref ref-type="bibr" rid="bibr2-0009922811430347">2</xref></sup> The recognition of epithelial barrier disruption at birth is important given the high risk of resultant infection and electrolyte imbalances; in fact, intravenous broad-spectrum antibiotics should be started until negative cultures return.<sup><xref ref-type="bibr" rid="bibr1-0009922811430347">1</xref></sup> To prevent infection, antibacterial soaps, oral anti-staphylococcal and gram-negative antibiotic coverage, and long-term application of mupirocin to nares to decrease staph colonization may be employed.<sup><xref ref-type="bibr" rid="bibr2-0009922811430347">2</xref></sup> Although topical keratolytics are occasionally recommended for these patients, they should be used with caution, as a large portion of the stratum corneum may be removed, resulting in denuded, raw skin.<sup><xref ref-type="bibr" rid="bibr2-0009922811430347">2</xref></sup> Patients may also complain of malodorous skin, which can be somewhat reduced by hypocholorite (diluted Clorox) and sodium bicarbonate baths.<sup><xref ref-type="bibr" rid="bibr2-0009922811430347">2</xref></sup></p>
</sec>
<sec id="section4-0009922811430347">
<title>Workup of Neonatal Blistering Disorders</title>
<p>It is important to make a definitive diagnosis when evaluating bullous disease in the neonate because underlying conditions may carry markedly different prognoses and recurrence risks (<xref ref-type="table" rid="table1-0009922811430347">Table 1</xref>).<sup><xref ref-type="bibr" rid="bibr1-0009922811430347">1</xref></sup> EB is the most common inherited bullous disorder, and patients may have a poor outcome compared with those with EHK.<sup><xref ref-type="bibr" rid="bibr1-0009922811430347">1</xref></sup> EB consists of 4 subtypes, each with different genes, sites of pathology, and modes of inheritance.<sup><xref ref-type="bibr" rid="bibr4-0009922811430347">4</xref></sup> Diagnostic tools to differentiate these different types of EB include immunomapping (the use of antibodies against known proteins in skin) and electron microscopy.<sup><xref ref-type="bibr" rid="bibr1-0009922811430347">1</xref></sup> Prenatal diagnosis is possible with fetoscopy and fetal skin biopsy, as well as with genetic testing on chorionic villus sampling or amniocentesis.<sup><xref ref-type="bibr" rid="bibr6-0009922811430347">6</xref></sup></p>
<table-wrap id="table1-0009922811430347" position="float">
<label>Table 1.</label>
<caption>
<p>The Major Inherited Bullous Diseases</p>
</caption>
<graphic alternate-form-of="table1-0009922811430347" xlink:href="10.1177_0009922811430347-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Disorder</th>
<th align="center">Inheritance Pattern</th>
<th align="center">Most Common Gene</th>
<th align="center">Onset</th>
<th align="center">Level of Blister</th>
<th align="center">Other Findings</th>
<th align="center">Prognosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epidermolytic hyperkeratosis</td>
<td>Autosomal dominant</td>
<td>Keratin 1, 10</td>
<td>Birth</td>
<td>Suprabasal layer of epidermis</td>
<td>Scaling skin</td>
<td>Symptoms may improve with age but may continue to have thick malodorous scale</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>Generalized erythroderma</td>
<td/>
</tr>
<tr>
<td>Ichthyosis bullosa of Siemens</td>
<td>Autosomal dominant</td>
<td>Keratin 2e</td>
<td>Birth</td>
<td>Superficial layers of epidermis</td>
<td><list list-type="simple">
<list-item><p>Scaling skin</p></list-item>
<list-item><p>Generalized erythroderma</p></list-item>
<list-item><p>Islands of normal skin</p></list-item></list></td>
<td>Symptoms improve with age</td>
</tr>
<tr>
<td>EB simplex</td>
<td>Autosomal dominant</td>
<td>Keratin 5, 14</td>
<td>Birth</td>
<td>Basal layer of epidermis</td>
<td>Healing without scarring</td>
<td>Symptoms improve with age</td>
</tr>
<tr>
<td>Junctional EB</td>
<td>Autosomal recessive</td>
<td>Laminin 5</td>
<td>Birth</td>
<td>Dermal–epidermal junction</td>
<td><list list-type="simple">
<list-item><p>Lethal form with central facial erosions</p></list-item>
<list-item><p>Dental defects</p></list-item>
<list-item><p>Nail dystrophy</p></list-item>
<list-item><p>Tracheal involvement</p></list-item>
</list></td>
<td>Lethal if generalized</td>
</tr>
<tr>
<td>Dystrophic EB</td>
<td>Autosomal dominant or autosomal recessive</td>
<td>Type VII collagen</td>
<td>Birth</td>
<td>Dermis</td>
<td><list list-type="simple">
<list-item><p>Hemorrhagic blisters</p></list-item>
<list-item><p>Healing with scarring</p></list-item>
<list-item><p>Esophageal strictures</p></list-item>
<list-item><p>Malformed teeth</p></list-item>
</list></td>
<td>Good in autosomal dominant cases; poor in autosomal recessive cases</td>
</tr>
<tr>
<td>Kindler syndrome</td>
<td>Autosomal recessive</td>
<td>FERMT1</td>
<td>Birth</td>
<td>Mixed</td>
<td><list list-type="simple">
<list-item><p>Dental defects</p></list-item>
<list-item><p>Anal stenosis</p></list-item>
<list-item><p>Phimosis</p></list-item>
</list></td>
<td>Many complications, but symptoms improve with age</td>
</tr>
<tr>
<td>Incontinentia pigmenti</td>
<td>X-linked dominant</td>
<td>NF-κB essential modulator protein (NEMO)</td>
<td>Birth or first few weeks of life</td>
<td>Mixed</td>
<td><list list-type="simple">
<list-item><p>Linear vesicles on extremities</p></list-item>
<list-item><p>Dental defects</p></list-item>
<list-item><p>Seizures</p></list-item>
</list></td>
<td>Depends on the extent of extracutaneous involvement</td>
</tr>
<tr>
<td>AEC syndrome</td>
<td>Autosomal dominant</td>
<td>TP63</td>
<td>Birth</td>
<td>Mixed</td>
<td><list list-type="simple">
<list-item><p>Cleft lip/palate</p></list-item>
<list-item><p>Ankyloblepharon</p></list-item></list></td>
<td>Poor</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0009922811430347">
<p>Abbreviations: EB, epidermolysis bullosa; AEC syndrome, ankyloblepharon–ectrodactyly–clefting syndrome.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The differential diagnosis of EHK and EB also includes ichthyosis bullosa of Siemens, ichthyosis hystrix, and peeling skin syndrome.<sup><xref ref-type="bibr" rid="bibr7-0009922811430347">7</xref></sup> Other genetic conditions that cause neonatal blistering include incontinentia pigmenti and ankyloblepharon–ectrodactyly–clefting (AEC) syndrome (Hay–Wells syndrome).<sup><xref ref-type="bibr" rid="bibr7-0009922811430347">7</xref></sup></p>
<p>Acquired conditions early in life can mimic EHK and EB and should be considered in the differential diagnosis of a neonate with blisters. Examples of acute, emergent conditions include staphylococcal scalded skin syndrome, bullous impetigo, Stevens–Johnson syndrome, and toxic epidermal necrolysis.<sup><xref ref-type="bibr" rid="bibr7-0009922811430347">7</xref></sup></p>
</sec>
<sec id="section5-0009922811430347">
<title>Conclusion</title>
<p>This case brings up several important issues. First of all, the accurate diagnosis of neonatal bullous disease is paramount, since conditions such as EHK and EB have significantly different prognoses and modes of inheritance. Also, it is essential that health care providers recognize the complications of bullous disease in neonates so that adequate treatment can be established in the NICU.</p>
</sec>
</body>
<back>
<ack>
<p>We appreciate the support of pediatric dermatologists Dr Ki-Young Suh, MD, and Dr Harry Saperstein, MD.</p>
</ack>
<fn-group>
<fn fn-type="conflict">
<label>Declaration of Conflicting Interests</label>
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article:</p>
<p>JMG is supported by the Steven Spielberg Pediatric Research Center, the NIH/NICHD Program Project Grant (HD36657), and the Medical Genetics NIH/NIGMS Training Program Grant (5-T32-GM08243).</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0009922811430347">
<label>1.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Freedberg</surname><given-names>IM</given-names></name>
<name><surname>Eisen</surname><given-names>AZ</given-names></name>
<name><surname>Wolff</surname><given-names>K</given-names></name>
<name><surname>Austen</surname><given-names>KF</given-names></name>
<name><surname>Goldsmith</surname><given-names>LA</given-names></name>
<name><surname>Katz</surname><given-names>SL</given-names></name>
</person-group>. <source>Fitzpatrick’s Dermatology in General Medicine</source>. <edition>6th ed.</edition> <publisher-loc>New York, NY</publisher-loc>: <publisher-name>McGraw-Hill</publisher-name>; <year>2003</year>.</citation>
</ref>
<ref id="bibr2-0009922811430347">
<label>2.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Spitz</surname><given-names>J</given-names></name>
</person-group>. <source>Genodermatoses: A Clinical Guide to Genetic Skin Disorders</source>. <publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>; <year>2005</year>.</citation>
</ref>
<ref id="bibr3-0009922811430347">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chamcheu</surname><given-names>JC</given-names></name>
<name><surname>Siddiqui</surname><given-names>IA</given-names></name>
<name><surname>Syed</surname><given-names>DN</given-names></name>
<name><surname>Adhami</surname><given-names>VM</given-names></name>
<name><surname>Liovic</surname><given-names>M</given-names></name>
<name><surname>Mukhtar</surname><given-names>H</given-names></name>
</person-group>. <article-title>Keratin gene mutations in disorders of human skin and its appendages</article-title>. <source>Arch Biochem Biophys</source>. <year>2011</year>;<volume>508</volume>:<fpage>123</fpage>-<lpage>137</lpage>.</citation>
</ref>
<ref id="bibr4-0009922811430347">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>DiGiovanna</surname><given-names>J</given-names></name>
<name><surname>Bale</surname><given-names>S</given-names></name>
</person-group>. <article-title>Clinical heterogeneity in epidermolytic hyperkeratosis</article-title>. <source>Arch Dermatol</source>. <year>1994</year>;<volume>130</volume>:<fpage>1026</fpage>-<lpage>1035</lpage>.</citation>
</ref>
<ref id="bibr5-0009922811430347">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arin</surname><given-names>MJ</given-names></name>
<name><surname>Oji</surname><given-names>V</given-names></name>
<name><surname>Emmert</surname><given-names>S</given-names></name><etal/>
</person-group>. <article-title>Expanding the keratin mutation database: novel and recurrent mutations and genotype-phenotype correlations in 28 patients with epidermolytic ichthyosis</article-title>. <source>Br J Dermatol</source>. <year>2011</year>;<volume>164</volume>:<fpage>442</fpage>-<lpage>447</lpage>.</citation>
</ref>
<ref id="bibr6-0009922811430347">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Luu</surname><given-names>M</given-names></name>
<name><surname>Cantatore-Francis</surname><given-names>JL</given-names></name>
<name><surname>Glick</surname><given-names>SA</given-names></name>
</person-group>. <article-title>Prenatal diagnosis of genodermatoses: current scope and future capabilities</article-title>. <source>Int J Dermatol</source>. <year>2010</year>;<volume>49</volume>:<fpage>353</fpage>-<lpage>361</lpage>.</citation>
</ref>
<ref id="bibr7-0009922811430347">
<label>7.</label>
<citation citation-type="book">
<person-group person-group-type="editor">
<name><surname>Rimoin</surname><given-names>DL</given-names></name>
<name><surname>Pyeritz</surname><given-names>RE</given-names></name>
<name><surname>Korf</surname><given-names>B</given-names></name>
</person-group>, eds. <source>Emery and Rimoin’s Principles and Practice of Medical Genetics</source>. <edition>6th ed.</edition> <publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>Elsevier.</publisher-name> <year>In press</year>.</citation>
</ref>
</ref-list>
</back>
</article>